Everett Collection / Shutterstock.com
HemoShear creates systems for predicting human responses to drugs by applying its proprietary technology to human cells in the lab to make them behave the way they would in vivo. LSIPR found out about its strategy for protecting and developing its technologies.
In the business of drug development, the biggest hurdle to clear is often the jump from pre-clinical testing, where the drug is screened for safety and efficacy in animals, to clinical testing, where it is first introduced into a human.
Many drugs fail at this point in their development but a serendipitous meeting of minds at the University of Virginia has presented a new hope for tackling an age-old problem.
Working models
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
News stories up to a week old and feature articles on the day of publication are accessible with a BASIC FREE ACCOUNT.
Register here for free content, or subscribe for access to archive.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’; and for basic access to the latest news on the website and weekly email news alerts choose the 'BASIC FREE ACCOUNT' registration.
HemoShear; Brian Wamhoff; patent protection;
